EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
A recent editorial1 by Mintzes and colleagues warns about using flawed clinical trials to approve new cancer drugs in Europe2 and the US.3 The implications go further, however: during the past…
